CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Acquires 6,551 Shares

Posted by George Bondi on Aug 6th, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) CEO Josh Mandel-Brehm purchased 6,551 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, for a total transaction of $10,809.15. Following the completion of the acquisition, the chief executive officer directly owned 284,968 shares of the company’s stock, valued at approximately $470,197.20. The trade was a 2.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

CAMP4 Therapeutics Trading Down 3.6%

Shares of CAMP stock opened at $4.01 on Thursday. CAMP4 Therapeutics Corporation has a 12-month low of $1.32 and a 12-month high of $7.75. The business’s fifty day simple moving average is $4.02 and its 200-day simple moving average is $4.31. The company has a market cap of $208.24 million, a PE ratio of -1.70 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, equities analysts forecast that CAMP4 Therapeutics Corporation will post -0.84 earnings per share for the current year.

More CAMP4 Therapeutics News

Here are the key news stories impacting CAMP4 Therapeutics this week:

Positive Sentiment: Insider buying signals management confidence. CEO Josh Mandel-Brehm, CFO Kelly Gold, Director Richard A. Young and insider Yuri Maricich collectively purchased 36,031 shares at $1.65 per share. The purchases increased their respective holdings, although the transactions were relatively small in dollar terms. Insider purchase filings
Positive Sentiment: CAMP4 raised approximately $50.1 million in the second closing of its private placement. The proceeds are intended to fund CMP-002, the company’s lead antisense oligonucleotide candidate, and its early-stage pipeline. The financing included participation from institutional investors such as Janus Henderson, Balyasny Asset Management, Vivo Capital and 5AM Ventures. CAMP4 private placement announcement
Positive Sentiment: CMP-002 moved closer to human testing. CAMP4 said it received Australian regulatory and ethics clearance to begin a Phase 1/2 trial for SYNGAP1-related disorder, a rare neurological disease with no approved disease-modifying therapies. Preclinical testing showed increased SYNGAP1 protein expression and improvements in disease-relevant animal models. CAMP4 financing and CMP-002 update
Negative Sentiment: The financing is materially dilutive. CAMP4 issued more than 10.7 million common shares and approximately 21.9 million pre-funded warrants at roughly $1.53 per share-equivalent, potentially expanding the share count significantly. The discounted issuance may weigh on the stock even though it provides additional operating runway.
Neutral Sentiment: Clinical execution remains the key catalyst and risk. The Phase 1/2 trial could provide important validation, but CMP-002 remains investigational and preclinical results do not guarantee safety or efficacy in humans.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CAMP shares. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Zacks Research downgraded CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Finally, Rodman & Renshaw began coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.36.

Read Our Latest Analysis on CAMP4 Therapeutics

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE purchased a new stake in CAMP4 Therapeutics in the 4th quarter valued at about $86,000. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the second quarter worth $36,000. Two Sigma Investments LP purchased a new stake in shares of CAMP4 Therapeutics in the 3rd quarter valued at $292,000. Vivo Capital LLC purchased a new position in CAMP4 Therapeutics during the 3rd quarter valued at about $11,765,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of CAMP4 Therapeutics in the fourth quarter valued at approximately $61,000.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.